Thyrocare Technologies Limited (hereinafter referred to as “THYROCARE” NSE: THYROCARE, BSE: 539871), a leading healthcare ...

Thyrocare Technologies Limited reported a robust 23% year-on-year revenue growth in Q1FY26. The company's core Pathology segment significantly contributed to this surge.

Thyrocare Technologies shares zoomed 12.66 per cent in trade, hitting a 52-week high at ₹1,356.95 per share on the BSE.

Thyrocare’s consolidated net profit rose 59.9% to INR 38.3 Cr in Q1 FY26 from INR 23.9 Cr in the year-ago quarter ...

Franchise-led expansion has been the key driver behind Thyrocare’s strong Q1 performance, with CEO Rahul Guha attributing the 23% revenue growth and 60% profit surge to the addition of 1,500 new ...

Thyrocare founder Dr. A Velumani sparks debate with his viral video criticizing the over-scheduling of city children. He ...

Dr A Velumani urged parents to rethink the pressures of over-scheduling in urban childhoods, advocating instead for a slower ...

Dr. A Velumani, Thyrocare's founder, advises parents against overindulging their children, emphasizing the crucial roles of ...

Thyrocare Technologies Limited reported a 62% year-on-year increase in profit after tax (PAT) to ₹38.06 crore for the quarter ended June 30, 2025. The company's revenue from operations grew by 23% to ...

Real-time updates on THYROCARE TECHNOLOGIES share price. Check out the detailed analysis of the company in this live blog.

Thyrocare Technologies surged 11.30% to Rs 1,340.55 after the healthcare service provider reported a 61.07% increase in consolidated net profit to Rs 38.93 crore on a 23.02% rise in revenue from ...

Thyrocare Technologies delivered excellent results in Q1. Both the company’s revenue and profit have increased. CEO Rahul Guha expressed optimism for faster growth in FY26. In an exclusive ...